|Bid||3.15 x 100|
|Ask||6.46 x 300|
|Day's range||5.98 - 6.29|
|52-week range||4.31 - 21.38|
|PE ratio (TTM)||N/A|
|Earnings date||6 Nov 2017 - 10 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.63|
Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Depomed, Inc. . The complaint is brought on behalf of all purchasers of Depomed securities between February 26, 2015 and August 7, 2017, for alleged violations of the Securities Exchange Act of 1934 by Depomed's officers and directors.
Glancy Prongay & Murray LLP reminds investors of the October 17, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Depomed, Inc.
October has been relatively quiet for Valeant Pharmaceuticals Internation (VRX), with little in the way of attention getting news. Yes, there have been some small successes in drug trials, and even a positive note from a Deutsche Bank analyst. Today, however, Valeant's stock has more than doubled its October loss after Wells Fargo's David Maris raised concerns about a lawsuit filed by Depomed (DEPO) over an alleged $20 million in unpaid royalties: In the grand scheme of Valeant’s issues, an unpaid $20 million bill barely rises to the level of investor concern.
Law Offices of Howard G. Smith reminds investors of the October 17, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Depomed, Inc.
Scott+Scott, Attorneys at Law, LLP , a national shareholder and consumer rights litigation firm, reminds investors that October 17, 2017, is the deadline to move for lead plaintiff status in the securities class action pending against Depomed, Inc.